ClinicalTrials.gov
public full text
Public Domain
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients#845417
- Anti-nephrin autoantibodies in post-transplant recurrence of focal segmental glomerulosclerosis: a review#669750
- Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes#1164296
- Association between the uric acid to high-density lipoprotein cholesterol ratio and estimated glomerular filtration rate decline in community-managed patients with type 2 diabetes: a retrospective cohort study.#412243
- An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis#283130
Record · ID 885681
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive